Refine
Year of publication
- 2024 (25)
- 2023 (101)
- 2022 (132)
- 2021 (145)
- 2020 (157)
- 2019 (192)
- 2018 (168)
- 2017 (154)
- 2016 (154)
- 2015 (176)
- 2014 (166)
- 2013 (171)
- 2012 (154)
- 2011 (184)
- 2010 (179)
- 2009 (185)
- 2008 (155)
- 2007 (149)
- 2006 (160)
- 2005 (130)
- 2004 (161)
- 2003 (106)
- 2002 (130)
- 2001 (106)
- 2000 (108)
- 1999 (109)
- 1998 (99)
- 1997 (99)
- 1996 (81)
- 1995 (78)
- 1994 (86)
- 1993 (59)
- 1992 (54)
- 1991 (29)
- 1990 (39)
- 1989 (45)
- 1988 (57)
- 1987 (32)
- 1986 (19)
- 1985 (34)
- 1984 (22)
- 1983 (20)
- 1982 (29)
- 1981 (20)
- 1980 (36)
- 1979 (24)
- 1978 (34)
- 1977 (14)
- 1976 (13)
- 1975 (12)
- 1974 (3)
- 1973 (2)
- 1972 (2)
- 1971 (1)
- 1968 (1)
Document Type
- Article (3226)
- Conference Proceeding (1146)
- Part of a Book (184)
- Book (144)
- Doctoral Thesis (30)
- Patent (25)
- Other (9)
- Report (9)
- Working Paper (6)
- Lecture (5)
- Poster (4)
- Preprint (4)
- Talk (4)
- Master's Thesis (2)
- Bachelor Thesis (1)
- Contribution to a Periodical (1)
- Habilitation (1)
Language
- English (4801) (remove)
Keywords
- Biosensor (25)
- Finite-Elemente-Methode (12)
- Einspielen <Werkstoff> (10)
- CAD (8)
- civil engineering (8)
- Bauingenieurwesen (7)
- Blitzschutz (6)
- FEM (6)
- Gamification (6)
- Limit analysis (6)
- Shakedown analysis (6)
- avalanche (6)
- shakedown analysis (6)
- Clusterion (5)
- Earthquake (5)
- Enterprise Architecture (5)
- MINLP (5)
- solar sail (5)
- Air purification (4)
- Diversity Management (4)
Institute
- Fachbereich Medizintechnik und Technomathematik (1668)
- Fachbereich Elektrotechnik und Informationstechnik (693)
- IfB - Institut für Bioengineering (620)
- Fachbereich Energietechnik (579)
- INB - Institut für Nano- und Biotechnologien (555)
- Fachbereich Chemie und Biotechnologie (534)
- Fachbereich Luft- und Raumfahrttechnik (477)
- Fachbereich Maschinenbau und Mechatronik (278)
- Fachbereich Wirtschaftswissenschaften (207)
- Solar-Institut Jülich (164)
- Fachbereich Bauingenieurwesen (153)
- ECSM European Center for Sustainable Mobility (79)
- MASKOR Institut für Mobile Autonome Systeme und Kognitive Robotik (67)
- Nowum-Energy (28)
- Fachbereich Gestaltung (25)
- Institut fuer Angewandte Polymerchemie (23)
- Sonstiges (21)
- Fachbereich Architektur (20)
- Freshman Institute (18)
- Kommission für Forschung und Entwicklung (18)
With a steady increase of regulatory requirements for business processes, automation support of compliance management is a field garnering increasing attention in Information Systems research. Several approaches have been developed to support compliance checking of process models. One major challenge for such approaches is their ability to handle different modeling techniques and compliance rules in order to enable widespread adoption and application. Applying a structured literature search strategy, we reflect and discuss compliance-checking approaches in order to provide an insight into their generalizability and evaluation. The results imply that current approaches mainly focus on special modeling techniques and/or a restricted set of types of compliance rules. Most approaches abstain from real-world evaluation which raises the question of their practical applicability. Referring to the search results, we propose a roadmap for further research in model-based business process compliance checking.
Breast cancer resistance protein (BCRP) is expressed in various tissues, such as the gut, liver, kidney and blood brain barrier (BBB), where it mediates the unidirectional transport of substrates to the apical/luminal side of polarized cells. Thereby BCRP acts as an efflux pump, mediating the elimination or restricting the entry of endogenous compounds or xenobiotics into tissues and it plays important roles in drug disposition, efficacy and safety. Bcrp knockout mice (Bcrp−/−) have been used widely to study the role of this transporter in limiting intestinal absorption and brain penetration of substrate compounds. Here we describe the first generation and characterization of a mouse line humanized for BCRP (hBCRP), in which the mouse coding sequence from the start to stop codon was replaced with the corresponding human genomic region, such that the human transporter is expressed under control of the murine Bcrp promoter. We demonstrate robust human and loss of mouse BCRP/Bcrp mRNA and protein expression in the hBCRP mice and the absence of major compensatory changes in the expression of other genes involved in drug metabolism and disposition. Pharmacokinetic and brain distribution studies with several BCRP probe substrates confirmed the functional activity of the human transporter in these mice. Furthermore, we provide practical examples for the use of hBCRP mice to study drug-drug interactions (DDIs). The hBCRP mouse is a promising model to study the in vivo role of human BCRP in limiting absorption and BBB penetration of substrate compounds and to investigate clinically relevant DDIs involving BCRP.
Generation and Characterization of a Novel Multidrug Resistance Protein 2 Humanized Mouse Line
(2012)
The multidrug resistance protein (MRP) 2 is predominantly expressed in liver, intestine, and kidney, where it plays an important role in the excretion of a range of drugs and their metabolites or endogenous compounds into bile, feces, and urine. Mrp knockout [Mrp2(−/−)] mice have been used recently to study the role of MRP2 in drug disposition. Here, we describe the first generation and initial characterization of a mouse line humanized for MRP2 (huMRP2), which is nulled for the mouse Mrp2 gene and expresses the human transporter in the organs and cell types where MRP2 is normally expressed. Analysis of the mRNA expression for selected cytochrome P450 and transporter genes revealed no major changes in huMRP2 mice compared with wild-type controls. We show that human MRP2 is able to compensate functionally for the loss of the mouse transporter as demonstrated by comparable bilirubin levels in the humanized mice and wild-type controls, in contrast to the hyperbilirubinemia phenotype that is observed in MRP2(−/−) mice. The huMRP2 mouse provides a model to study the role of the human transporter in drug disposition and in assessing the in vivo consequences of inhibiting this transporter by compounds interacting with human MRP2.
Compared with rodents and many other animal species, the human cytochrome P450 (P450) Cyp2c gene cluster varies significantly in the multiplicity of functional genes and in the substrate specificity of its enzymes. As a consequence, the use of wild-type animal models to predict the role of human CYP2C enzymes in drug metabolism and drug-drug interactions is limited. Within the human CYP2C cluster CYP2C9 is of particular importance, because it is one of the most abundant P450 enzymes in human liver, and it is involved in the metabolism of a wide variety of important drugs and environmental chemicals. To investigate the in vivo functions of cytochrome P450 Cyp2c genes and to establish a model for studying the functions of CYP2C9 in vivo, we have generated a mouse model with a deletion of the murine Cyp2c gene cluster and a corresponding humanized model expressing CYP2C9 specifically in the liver. Despite the high number of functional genes in the mouse Cyp2c cluster and the reported roles of some of these proteins in different biological processes, mice deleted for Cyp2c genes were viable and fertile but showed certain phenotypic alterations in the liver. The expression of CYP2C9 in the liver also resulted in viable animals active in the metabolism and disposition of a number of CYP2C9 substrates. These mouse lines provide a powerful tool for studying the role of Cyp2c genes and of CYP2C9 in particular in drug disposition and as a factor in drug-drug interaction.
Table of Contents Introduction 1. Generative Manufacturing Processes 2. Classification of Generative Manufacturing Processes 3. Application of Generative Processes on the Fabrication of Ceramic Parts 3.1 Extrusion 3.2 3D-Printing 3.3 Sintering – Laser Sintering 3.4 Layer-Laminate Processes 3.5 Stereolithography (sometimes written: Stereo Lithography) 4. Layer Milling 5. Conclusion - Vision